Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia

(2013) A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology.

Full text not available from this repository.

Official URL:


Rational: A growing body of evidence illustrates that 5-HT3 receptor antagonist drugs may be of benefit in the treatment of negative symptoms in schizophrenia. Objective: The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia. Methods: In a double-blind, placebo-controlled 8-week trial, 40 patients with chronic schizophrenia who were stabilized on risperidone were randomized into tropisetron or placebo add-on groups. Psychotic symptoms were measured using the Positive and Negative Syndrome Scale (PANSS) every 2 weeks. Furthermore, extrapyramidal and depressive symptoms as well as side effects were assessed. The primary outcome measure was the difference in change from baseline of negative subscale scores between the two groups at week 8. Results: Tropisetron resulted in greater improvement of the total PANSS scores F(1.860,70.699) = 37.366, p < 0.001 as well as negative scores F(2.439,92.675) = 16.623, p < 0.001 and general psychopathology F(1.767,67.158) = 4.602, p = 0.017, but not positive subscale scores F(1.348, 51.218) = 0.048, p = 0.893 compared to placebo. In a multiple regression analysis controlling for positive, extrapyramidal, and depressive symptoms, treatment group (standardized β = -0.640) significantly predicted changes in primary negative symptoms. The side effect profile did not differ significantly between the two groups. Conclusion: Tropisetron add-on to risperidone improves the primary negative symptoms of patients with chronic stable schizophrenia. © 2013 Springer-Verlag Berlin Heidelberg.

Item Type: Article
Keywords: placebo; risperidone; tropisetron, abdominal pain; add on therapy; adult; agitation; article; clinical article; constipation; controlled study; decreased appetite; depression; diarrhea; dizziness; double blind procedure; drowsiness; drug efficacy; drug tolerability; extrapyramidal symptom; extrapyramidal symptom rating scale; fatigue; female; Hamilton scale; human; increased appetite; male; multicenter study; nausea; negative syndrome; parallel design; Positive and Negative Syndrome Scale; priority journal; psychological rating scale; randomized controlled trial; schizophrenia; side effect, Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Indoles; Male; Regression Analysis; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists; Severity of Illness Index; Treatment Outcome
Page Range: pp. 595-602
Journal or Publication Title: Psychopharmacology
Volume: 228
Number: 4
Identification Number: 10.1007/s00213-013-3064-2
ISSN: 00333158
Depositing User: مهندس جمال محمودپور

Actions (login required)

View Item View Item